Plerixafor

From Wikipedia, the free encyclopedia

Plerixafor
IUPAC name	1,1'-[1,4-Phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane] octohydrobromide dihydrate
Identifiers
CAS number	[155148-31-5]
PubChem	65015
MeSH	JM+3100
Properties
Molecular formula	C28H54N8
Molar mass	502.782 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references

Plerixafor (rINN and USAN, also known as MOZOBIL, JM 3100 and AMD3100) is a macrocyclic compound and potential fusion inhibitor. It is an antagonist (or perhaps more accurately a partial agonist) of the alpha-chemokine receptor CXCR4.

Contents 1 Research 1.1 HIV 1.2 Mobilization of hematopoietic stem cells 1.3 Small molecule cancer therapy 2 References

[edit] Research

[edit] HIV

It was initially developed for potential use in the treatment of HIV, for its role in the blocking of CXCR4, a chemokine receptor which acts as a co-receptor for certain strains of HIV (along with the virus's main cellular receptor, CD4). However, clinical trials in patients with HIV-AIDS have to date shown relatively little useful anti-viral activity.

Further information: Entry inhibitors

[edit] Mobilization of hematopoietic stem cells

However, the CXCR4 alpha-chemokine receptor and its ligand SDF-1 are also important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem cell quiescence. Plerixafor has been found to be a strong inducer of "mobilization" of hematopoietic stem cells from the bone marrow to the bloodstream as peripheral blood stem cells.^[1]

Peripheral blood stem cell mobilization, which has become extremely important as a source of hematopoietic stem cells for transplantation over the past 10 to 15 years, is generally performed using the cytokine drug G-CSF, but is ineffective in around 15 to 20% of patients. AMD3100 offers clinical promise as a drug for peripheral blood stem cell mobilization, and has recently completed Phase 3 clinical trials.^[2] It is not yet in routine clinical use.

Mozobil has orphan drug status in the United States and European Union. Once approved by regulatory authorities,Genzyme intends to commercialize (market) Mozobil to hematologists and hematopoietic stem cell transplant centers worldwide. Genzyme acquired Mozobil when it bought AnorMED, Inc. in 2006.

[edit] Small molecule cancer therapy

AMD3100 was seen to decrease metastasis in mice in several studies.^[3]

[edit] References

1. ^ Cashen A, Nervi B, DiPersio J (2007). "AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent". Future Oncol 3 (1): 19–27. doi:10.2217/14796694.3.1.19. PMID 17280498. 
2. ^ "Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791" (2007). Drugs R D 8 (2): 113–9. PMID 17324009. 
3. ^ "CXCR4 regulates growth of both primary and metastatic breast cancer." (2004). Cancer Research 64 (23): 8604–8612. doi:10.1158/0008-5472.CAN-04-1844. PMID 15574767.